Disclosure of clinically actionable genetic variants to thoracic aortic dissection biobank participants
Abstract Background Disclosure of pathogenic variants to thoracic aortic dissection biobank participants was implemented. The impact and costs, including confirmatory genetic testing in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, were evaluated. Methods We exome sequenc...
Main Authors: | Adelyn Beil, Whitney Hornsby, Wendy R. Uhlmann, Rajani Aatre, Patricia Arscott, Brooke Wolford, Kim A. Eagle, Bo Yang, Jennifer McNamara, Cristen Willer, J. Scott Roberts |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | BMC Medical Genomics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12920-021-00902-5 |
Similar Items
-
Pathology and Biobanking
by: Canan KELTEN TALU, et al.
Published: (2020-05-01) -
An Australian Chronic Kidney Disease Biobank to Support Future Research
by: Evan P. Owens, et al.
Published: (2019-05-01) -
Biobank@VITO: Biobanking the General Population in Flanders
by: Rosette Van Den Heuvel, et al.
Published: (2020-02-01) -
Harmonization of Biobank Education for Biobank Technicians: Identification of Learning Objectives
by: Mara Lena Hartung, et al.
Published: (2021-04-01) -
Biobanking in health care: evolution and future directions
by: Luigi Coppola, et al.
Published: (2019-05-01)